• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

I'm Putting a Marker Down on 'Blue' for 2020

Here's my stock pick for the year ahead.
By BRUCE KAMICH
Dec 31, 2019 | 06:00 AM EST
Stocks quotes in this article: IBM

It's that time of year again when financial writers give you a summary of what happened in the past 12 months and endeavor to predict what single stock could be a home run this coming year. It is an interesting exercise, although I think it is like putting all your money on one number in roulette.

Despite that quibble I will add my two cents to the mix this year. I think the stock performance of IBM (IBM) can surprise on the upside in 2020. 

Let's pay a visit to the charts and indicators so I can give you my spin on the technical condition of IBM. 
 
In the daily bar chart of IBM, below, we can see that prices have been trading sideways for much of the past year. Dips to around the $130-$125 area have been bought and slightly higher lows can be seen from May to August to December. Lower highs can also be seen from July to September to November. The pattern of trading is coming to an apex and ideally an upside breakout. Prices are below the flat 200-day moving average line and just above the 50-day moving average line. A rally to $140 will improve the technical picture.
 
The On-Balance-Volume (OBV) has been trending sideways from July, suggesting that traders and investors have continued to hold long positions in IBM in 2019. The Moving Average Convergence Divergence (MACD) oscillator has made higher lows from late August and is now close to crossing the zero line for an outright go long signal. 

In the weekly bar chart of IBM, below, we can see the past three years of activity. Prices are below the flat 40-week moving average line.

The weekly OBV line has been steady the past year and the MACD oscillator is only slightly below the zero line so a price advance could move this indicator back to a buy.  

 
In this weekly close only Point and Figure chart of IBM, below, we can see a potential upside price objective of $201 being projected.  
 

Bottom-line strategy: I think the price gains in 2020 will be front loaded in the first two quarters of the year. If I had to call a top I would anticipate that the middle of April might be the best time to take profits. Looking at IBM I would recommend going long around $135 and risking a weekly close below $130. The $200 area is our price objective for the first half of 2020. 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Fintech | Software & Services | Technology | Technology Hardware & Equipment |

More from Stocks

You Can Invest in Micron, But Here's Why You May Want to Wait

Stephen Guilfoyle
Jul 1, 2022 10:15 AM EDT

MU reported earnings Thursday night and the guidance was shocking.

The Charts Point to More Selling Ahead for 4 Former Tech Leaders

Ed Ponsi
Jul 1, 2022 10:00 AM EDT

Keep in mind that no matter how much a stock has fallen, it can always go lower, and it appears these four stocks could prove that point.

Enanta Pharmaceuticals Bounces Off a Key Support Level Once Again

Bruce Kamich
Jul 1, 2022 9:41 AM EDT

The shares of the biotech company appear to be finding a bottom but could use more sideways action to create a better base.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

A Few Thoughts on How to Approach a Tougher Bear Market Than Most

Bob Byrne
Jul 1, 2022 8:30 AM EDT

A key goal is to keep from losing money while the current bear runs its course, and don't count on positive seasonality leading to the Fourth of July.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login